varian competit posit remain strong even
updat forecast estim jun
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jun
estim jun
price data jun
rate updat jun
currenc amount express
valuat growth profit
methodolog valu compani
buoy grow demand radiotherapi rt varian main
competitor elekta enjoy sale momentum next
decad particularli emerg market rt industri
consolid substanti past decad two
compani prime posit benefit believ
mid-single-digit growth marketplac
focu drug
therapi
investor seek capitalis futur cancer treatment
pizzazz cancer drug market growth
prospect rather attract earli stage rt
adopt latest advanc technolog allow higher
dosag precis deliveri radiat address mani
concern surround rt significantli expand potenti
rt opportun particularli attract emerg market
utilis rate significantli trail develop
world demograph westernis emerg
market drive cancer incid higher demand rt
acceler significantli yet still massiv gap
current rt instal base need meet grow
demand estim market support twice mani
platform without approach develop world standard
varian elekta stand benefit trend
forecast call close world rt equip
instal provid two compani next
decad varian exposur matur market limit
growth prospect compani scale strong suit
product allow captur major global linac
without imag busi varian return competit
posit look attract varian focu proton
therapi like drag result near futur
altern tradit rt strong long-term potenti
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
varian medic system design manufactur sell radiat
technolog use two busi segment oncolog system proton
therapi america account largest portion revenu
follow europ middl east africa asia-pacif
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit jun
increas fair valu estim per share
due cash flow realis sinc last updat
expect varian domin global posit result
captur rate roughli equal instal base
market share even split elekta elsewher
forecast varian entir instal base grow
unit current repres
roughli instal base market share
forecast geographi product mix evolv
asia-pacific/softwar servic presenc expect
oncolog sale america repres less
total oncolog sale percentag point
servic softwar sale grow rate
basi point higher hardwar
trend occur elsewher although hardwar
placement emerg market still repres main
portion sale
varian gradual shift toward aftermarket sale allow
gross margin expand gradual offset potenti
price pressur chang geographi mix forecast
call gross margin pariti elekta varian
varian overal cost structur remain lower given
scale compani continu see oper
leverag earn growth averag close
throughout forecast
varian fair valu estim rang per share
bear-cas scenario per share bull-cas
scenario key driver forecast revenu
growth margin expans believ entir rt
industri grow mid-single-digit rate
risk assumpt mainli deterior
 marketplac unexpect aggress price
strategi emerg market event would depress
varian growth particular given outsiz exposur
 low-single-digit growth consid
scenario like given benefit rt age platform
instal base low incent start
price war howev scenario margin stay flat
slightli declin earn growth averag
rather minuscul versu greater
histor strip benefit varian econom
moat fair valu estim declin upsid
case assum fairli rapid growth western europ rt
adopt rate pickup upgrad cycl
double-digit growth emerg market
addit margin expans varian earn grow
mid- high teen rate proton therapi wild card
valuat treatment becom mainstream could
repres radio treatment end next
decad case varian could see proton revenu rise
dramat proton servic carri particularli
flip side mani uncertainti surround
proton temper enthusiasm
uncertainti rate base scenario analysi
compani world involv
radiotherapi varian elekta account
lion share new instal siemen
bow market rt equip
characteris high barrier entri owe
know-how high switch cost aris
signific train cost disrupt risk start
decad ago rather fragment field
evolv essenti duopoli new entrant
decad main two player built
durabl franchis mind upgrad
intellectu properti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
world rt instal expect field becom
concentr vast major replac
instal greenfield expect go either
varian elekta stickier custom base
entri barrier also increas expect
global market share platform instal reflect
belief two firm compel
offer marketplac
varian posit proton strong get
stronger main competitor lack resourc
global presenc varian said proton still
earli stage develop first-mov
advantag import entir sold futur
marketplac believ varian better
posit peer space varian main
competitor iba world-wide focus sole proton
howev iba lack deep pocket varian proton
technolog clinic data thu assum varian
end winner area although whether ever
earn return similar achiev linac yet
determin
consid compani wide econom moat
sever moat sourc consid
expand mainli switch cost emerg
network effect varian elekta posit rel
fairli stabl switch cost alreadi
strong thank long shelf life linac averag
life span machin eight year depend
custom signific price tag train cost
associ rt equip furthermor
absenc signific bodi academ clinic data
intang asset moat sourc new entrant space
varian econom moat rate wide narrow
combin high herfindahl ratio signific barrier
entri moder degre rivalri posit rt
favour rel sever devic
segment despit potenti price pressur
emerg market custom
cost-consci consid degre rivalri
key player moder expect firm
engag cutthroat value-destroy price war
price point hardwar emerg market may end
lower opportun upsel custom
eventu off-set initi discount addit
sticki custom base razor/razor blade busi model
offer ampl opportun high-margin/high-return
aftermarket sale entir rt market expect
grow mid- high singl digit strong
stimuli firm compet aggress
varian largest rt manufactur
market share global even domin posit
 control roughli instal
elekta second-largest player roughli fourth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
chanc establish player given
life-sav natur machin along high
risk oper oncologist familiar softwar
also
competitor
develop treatment plan share softwar
potenti entrench exist competitor
creat network effect would give varian elekta
edg get greenfield instal howev
vast major new order split two firm
forecast strengthen posit rel
remaind field becom less meaning versu
head-to-head comparison view competit
dynam stabl thu firm carri stabl moat trend
rate varian competit posit proton
improv steadili particularli roll-out
single-room platform enough affect overal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ovarian invest softwar busi
pay compani take share elekta
particularli treatment plan side
ovarian opt pursu mr-rt elekta
endeavour area prove success could
forc varian play catch-up
oproton potenti significantli disrupt
radio-oncolog field varian advantag
elekta pure-play proton player
virtual
untouch close exist instal
base need upgrad bode well
firm latest product introduct
oproton therapi interest grow field
cost requir instal well
limit clinic data could hinder adopt
ovarian exposur freestand clinic rel
minor free clinic consolid
acquir larger hospit sever platform due
replac probabl come market entir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
varian healthi balanc sheet carri littl
debt compani cash flow robust steadi
minimis concern solvenc
key concern rt industri futur
reimburs trend replac natur
 market slow adopt rt western europ
aggress competit emerg market
center medicar medicaid servic reimburs
rate mix bag industri one hand
hospit rate particularli emerg technolog
imrt receiv steadi increas free-stand
oper squeez howev long two
compani continu demonstr effect rt
anticip rather friendli industri
given low cost rt rel overal cancer
treatment industri western europ much forecast
hing abil willing central govern
invest rt equip bring usag par
 also cost-consci consum emerg
market rais risk disciplin price
world could
deterior softwar servic crucial
compon firm strategi growth stori
revenu sourc could perceiv
deploy capit payoff certain initi
varian invest proton therapi elekta
mri-en linac uncertain proton particular could
riski endeavor varian willing financ
construct proton facil expos credit risk
evidenc recent write-down scripp loan
final must awar develop outsid
cancer treatment certain emerg
treatment immuno-oncolog could dramat
alter current treatment paradigm believ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
radiotherapi remain relev even immuno-oncolog
prove disrupt forc growth trajectori may
affect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
septemb wilson took ceo follow
timothi guertin retir wilson work
compani variou capac sinc includ
presid oncolog system busi
wilson compani seem much focus
aftermarket sale critic long-term growth
term capit alloc manag decis
solid acquisit target smaller firm give
varian access emerg technolog softwar
invest proton therapi highli
uncertain payoff profil shield firm
disrupt caus emerg therapi manag
commit imag busi test
varian final spun busi believ
correct decis competit posit
imag deterior dramat right ship
would requir capit invest would distract
varian flagship rt busi manag
decis abandon sirtex also prudent one view
repres date owner name posit common share held report holder issuer
govern pension fund norway global
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
varian second-quart result full-year forecast
organ currency-neutr basi remain line
expect maintain fair valu estim
per share share ralli significantli
past year stock trade moder premium
valuat maintain wide moat rate
varian revis guidanc revenu
line due favor currenc healthi
albeit in-lin revenu growth first six month
provid support full-year forecast compani
still see strength halcyon emerg market
software/servic propel second-quart revenu
growth constant currenc order growth
bit lighter forecast constant currenc
america emea asia-pacif order growth
low singl digit long-term trajectori
radiotherapi compani might see slight
demand delay anticip halcyon approv asia
approv halcyon demand strong
varian place unit nearli half go greenfield
softwar servic strong quarter
softwar revenu servic compani
continu expand rapidplan instal base
quarter still signific
opportun remain rapidplan current instal
varian total platform base servic
revenu uptick partli due region mix strong
growth instal develop market carri high
servic attach rate typic higher contract
growth compani becom less expos capit
varian deliv in-lin perform bottom line
gross oper margin show
improv believ firm meet revis
neutral varian acquisit sirtex jan
acquisit sirtex varian expand
tangenti area oncolog treatment hold
rather restrain opinion sirtex product portfolio
futur potenti varian pay billion sirtex
signific premium current market price
fair valu estim sirtex view
deal particularli impact valuat
transact first major deal varian carri
recent histori exclud dispos imag
busi maintain valuat moat rate
varian rais fair valu estim sirtex
match offer price anticip deal close
expect
sirtex develop novel embol radiat therapi
devic treat inoper liver cancer devic involv
infus radioact microspher target liver
tumour sir-spher current larg confin use
salvag therapi -- last measur tradit
approach fail howev firm eye
much larger market second- first-lin set
advanc liver cancer nevertheless expans
larg conting success sever on-going clinic
trial far result disappoint
larg due single-product statu award
sirtex moat think challeng varian
significantli expand product market model
sirtex assum moder mid-single-digit
growth modest margin expans pay time
ebit multipl busi creat much valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
order far success rapidplan veloc also
larg account forecast nonetheless
compani market share gain softwar busi
varian deliv strong perform bottom line
gross oper margin show
improv believ compani exceed
revis earn guidanc maintain forecast
varian unless compani see recent clinic trial
failur setback rather long-term impedi
broader expans could see varian util global
presenc increas awar sir-spher
firm like abl extract moder cost synergi
howev upsid deal great view
first-quart result full-year
forecast strong rais fair valu
estim modestli per share mainli account
cash flow realiz sinc previou report share
ralli significantli past year stock trade
moder premium updat valuat
maintain wide moat rate firm
state clearli note previou quarter
varian forecast conserv
perplex growth estim oncolog
busi opt maintain growth
forecast saw good upsid halcyon
platform continu strength nonhardwar
busi mind compani revis guidanc
heel impress first-quart
result particularli surpris us anticip
strength inde come halcyon emerg market
software/servic furthermor alreadi
model lower long-term tax rate anoth
factor upgrad guidanc
said remain impress varian steadili strong
result especi compar uneven perform
main competitor elekta halcyon hit
emerg market adopt platform
larg expect also cost-consci develop
market surprisingli account
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
